A novel artificial intelligence (AI) application capable of diagnosing endocrine cancers with speed and accuracy is being presented Sunday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.

The research, presented by Jansi Rani Sethuraj, B.S.N., R.N., C.C.R.N., from the University of Texas Health Science Center at Houston, introduces a universally accessible and computationally efficient AI application. This AI application aims to democratize expert-level cancer diagnostics, making them available on basic internet-connected devices, including smartphones.

Endocrine cancers, affecting organs such as the thyroid, ovary, pancreas, pituitary, and adrenal glands, pose unique challenges due to their complex hormonal effects and difficult diagnostic profiles. With an estimated 10 million cancer-related deaths each year, the need for innovative, scalable diagnostic solutions is imminent.

This new AI-powered tool leverages advanced deep learning architectures, such as EfficientNet and ResNet, to analyze diverse medical data, including computerized tomography (CT) scans, magnetic resonance imaging (MRI), ultrasonography (USG), and histopathology images, enabling comprehensive and accurate cancer detection.

According to Sethuraj, the AI models demonstrated exceptional diagnostic accuracy, reportedly exceeding 99% in certain validation datasets across multiple endocrine cancer types. These results align with recent studies showing AI can achieve high accuracy in endocrine tumor classification, though real-world performance may vary.

Two researchers, Ramya Elangovan and Kavin Elangovan of AIM Doctor in Houston, Texas, curated anonymized endocrine cancer image datasets representing diverse populations spanning six continents. These images were used to train and validate deep learning models capable of detecting and staging multiple endocrine cancers with very high accuracy.

The application’s reliability and usability were independently evaluated by health care professionals from multiple international institutions, highlighting its potential for global applicability. The application’s streamlined design enables rapid image analysis, processing each image in under one second, even on devices with limited computational resources.

By enabling clinicians and primary care providers to access expert-level diagnostic support anywhere, this technology has the potential to reduce diagnostic errors, accelerate treatment decisions, and improve patient outcomes globally, especially in resource-limited settings.

“By democratizing access to advanced diagnostics, this AI innovation marks a paradigm shift in cancer care, offering hope for earlier detection, more precise treatment, and better survival for patients facing endocrine malignancies,” said the chief mentor of this project, Elangovan Krishnan, M.B., B.S., P.G.D.H.M., M.Tech., M.S., Ph.D., of AIM Doctor.

“This AI-powered application can deliver fast, reliable, and affordable endocrine cancer diagnostics to anyone, anywhere, thereby helping to close gaps in cancer care and advance health equity worldwide.”

The study is titled, “A Universally Accessible, Computationally Efficient, Artificial Intelligence Powered Application for Diagnosing Endocrine Cancers,” and it will be presented on Sunday, July 13.